7/23/2009

Takeda Pharmaceutical said the FDA moved to Sept. 4 its deadline to decide whether to approve a drug that blends diabetes drugs Actos and alogliptin. Review of the fixed-dose combination is separate from Takeda's application for alogliptin, which failed to gain FDA approval last month.

Full Story:
Bloomberg

Related Summaries